JP2023182231A - Ｓａｒｓ－ｃｏｖ－２ ｓ糖タンパク質エクトドメインを含むプロテオリポソームおよびワクチンとしてのそれらの使用 - Google Patents

Ｓａｒｓ－ｃｏｖ－２ ｓ糖タンパク質エクトドメインを含むプロテオリポソームおよびワクチンとしてのそれらの使用 Download PDF

Info

Publication number
JP2023182231A
JP2023182231A JP2022095715A JP2022095715A JP2023182231A JP 2023182231 A JP2023182231 A JP 2023182231A JP 2022095715 A JP2022095715 A JP 2022095715A JP 2022095715 A JP2022095715 A JP 2022095715A JP 2023182231 A JP2023182231 A JP 2023182231A
Authority
JP
Japan
Prior art keywords
amino acid
cov
sars
protomers
glycoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022095715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023182231A5 (https=
Inventor
ヴァイセンホルン，ヴィンフリート
Weissenhorn Winfried
スルバラン・マチャド，グイデン
Sulbaran Machado Guidenn
ギリゲイ，デルフィーヌ
Girigeo Delphine
エファンタン，グレゴリー
Effantin Gregory
アーメン，アクセル
Amen Axel
ポワナール，パスカル
Poignard Pascal
ル・グラン，ロジェ
Le Grand Roger
メゾナス，ポリーヌ
Maisonnasse Pauline
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Centre Hospitalier Universitaire de Grenoble
Universite Grenoble Alpes
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Commissariat a lEnergie Atomique CEA
Centre Hospitalier Universitaire de Grenoble
Universite Grenoble Alpes
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Commissariat a lEnergie Atomique CEA, Centre Hospitalier Universitaire de Grenoble, Universite Grenoble Alpes, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Centre National de la Recherche Scientifique CNRS
Priority to JP2022095715A priority Critical patent/JP2023182231A/ja
Publication of JP2023182231A publication Critical patent/JP2023182231A/ja
Publication of JP2023182231A5 publication Critical patent/JP2023182231A5/ja
Pending legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2022095715A 2022-06-14 2022-06-14 Ｓａｒｓ－ｃｏｖ－２ ｓ糖タンパク質エクトドメインを含むプロテオリポソームおよびワクチンとしてのそれらの使用 Pending JP2023182231A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022095715A JP2023182231A (ja) 2022-06-14 2022-06-14 Ｓａｒｓ－ｃｏｖ－２ ｓ糖タンパク質エクトドメインを含むプロテオリポソームおよびワクチンとしてのそれらの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2022095715A JP2023182231A (ja) 2022-06-14 2022-06-14 Ｓａｒｓ－ｃｏｖ－２ ｓ糖タンパク質エクトドメインを含むプロテオリポソームおよびワクチンとしてのそれらの使用

Publications (2)

Publication Number Publication Date
JP2023182231A true JP2023182231A (ja) 2023-12-26
JP2023182231A5 JP2023182231A5 (https=) 2025-05-29

Family

ID=89310023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022095715A Pending JP2023182231A (ja) 2022-06-14 2022-06-14 Ｓａｒｓ－ｃｏｖ－２ ｓ糖タンパク質エクトドメインを含むプロテオリポソームおよびワクチンとしてのそれらの使用

Country Status (1)

Country Link
JP (1) JP2023182231A (https=)

Similar Documents

Publication Publication Date Title
Vogel et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2
CN111991556B (zh) SARS-CoV-2 RBD共轭纳米颗粒疫苗
US20230285539A1 (en) Vaccines against sars-cov-2 and other coronaviruses
EP3024483B1 (en) Conformationally stabilized rsv pre-fusion f proteins
EP2953966B1 (en) Induction of cross-reactive cellular response against rhinovirus antigens
US20230174588A1 (en) A vaccine against sars-cov-2 and preparation thereof
Vogel et al. BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2
CN103476788A (zh) 免疫原性屈曲病毒肽
US20250345413A1 (en) Sars-cov-2 subunit vaccine
US20220175910A1 (en) Novel influenza antigens
JP2023519837A (ja) コロナウイルスを処置するためのワクチン組成物
Sulbaran et al. Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection
TW202208400A (zh) 來自ｓａｒｓ–ｃｏｖ–２之保守肽抗原決定基於開發廣泛型ｃｏｖｉｄ–１９疫苗之用途
EP3522919A1 (en) Vaccine
CA3162727A1 (en) Proteoliposomes comprising a sars-cov-2 s glycoprotein ectodomain and their use as a vaccine
US20220339279A1 (en) Recombinant proteins, compositions, vectors, kits, and methods for immunizing against, and testing for exposure to, severe acute respiratory syndrome coronavirus 2
JP2023182231A (ja) Ｓａｒｓ－ｃｏｖ－２ ｓ糖タンパク質エクトドメインを含むプロテオリポソームおよびワクチンとしてのそれらの使用
US20240002446A1 (en) Proteoliposomes comprising a sars-cov-2 s glycoprotein ectodomain and their use as a vaccine
US20240261389A1 (en) Amino acids, nucleotides and vectors expressing the same and uses thereof in preventing sarbecovirus infection
CN115322247B (zh) 一种新型冠状病毒受体结合区电荷突变体抗原及应用
Li et al. Fusion of C3d with hemagglutinin enhances protective immunity against swine influenza virus
KR20240168483A (ko) 리노바이러스 백신
EP4710948A1 (en) A recombinant sars-cov-2 s glycoprotein trimer, proteoliposomes comprising such a trimer and their use as a vaccine
Kim et al. Development of Nanobody-Expressing Nanosomes for Neutralization of Influenza Virus
WO2022155649A1 (en) Herpes simplex virus type 1 derived influenza vaccine

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20220711

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250520

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20250703

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260414